06/25/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/23/2025
3:08 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2025
5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/23/2025
5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/21/2025
1:11 PM | Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/15/2025
3:27 PM | Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/01/2025
4:47 PM | Arbutus Biopharma (Issuer)
Nguyen Tuan (Reporting)
| Form 4/A | |
03/31/2025
8:42 AM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/27/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/27/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for ABUS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. |
03/24/2025
8:19 AM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/20/2025
3:08 PM | Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2025
3:10 PM | Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2025
8:34 AM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/07/2025
1:59 PM | Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/06/2025
3:07 PM | Arbutus Biopharma (Issuer)
Gline Matthew (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:08 PM | Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:10 PM | Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:11 PM | Arbutus Biopharma (Issuer)
Bishop Joseph E (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2025
3:13 PM | Arbutus Biopharma (Issuer)
Hasija Anuj (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/03/2025
8:24 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/25/2025
6:05 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/25/2025
6:19 AM | Arbutus Biopharma (Subject)
Roivant Sciences Ltd. (Filed by)
Roivant Sciences Ltd. (Filed by)
| Form SCHEDULE 13D/A | |
02/21/2025
8:00 AM | Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
| Form SCHEDULE 13D/A | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
Sims Karen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
HASTINGS DAVID C (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
McElhaugh Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
5:25 PM | Arbutus Biopharma (Issuer)
Naftzger J. Christopher (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/04/2025
7:34 PM | Arbutus Biopharma (Subject)
Naftzger J. Christopher (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
7:36 PM | Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
7:38 PM | Arbutus Biopharma (Subject)
Sims Karen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
7:39 PM | Arbutus Biopharma (Subject)
HASTINGS DAVID C (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/03/2025
2:26 PM | Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
11:15 PM | Arbutus Biopharma (Filer)
| Form EFFECT | |
11/15/2024
10:03 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
7:41 AM | Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
| Form SC 13G/A | |
11/06/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/15/2024
7:26 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/11/2024
3:07 PM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Google did what!?!? (Ad) A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.”
Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free. Gates and Altman are betting big—see why |
08/01/2024
6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Free ABUS Stock Alerts